This article originally posted 15 February, 2005 and appeared in Issue 247
Eli Lilly's Ruboxistaurin Poised to Transform the Diabetic Neuropathy Drug Marke
Ruboxistaurin can possibly shift the market from pain control to disease modification, according to a new report from Decision Resources.
Advertisement
According to the new Pharmacor study entitled Diabetic Neuropathy, Eli Lilly's
ruboxistaurin promises to be the first drug with disease-modifying potential
that will launch beyond Japan. (Epalrestat, available in Japan since 1995, is
thought by physicians to be only moderately effective.)
"Although ruboxistaurin has performed poorly in trials for diabetic retinopathy,
interviewed experts remain hopeful that, if this agent is administered early
enough in the disease process, it will reduce disease progression of distal
symmetrical polyneuropathy, the most common clinical manifestation of neuropathy
among diabetics," said Carilee Berg, Ph.D., analyst at Decision Resources.
Decision Resources, Inc, Report
==============================
Learn about Dr. Richard K. Bernstein's new 5 CD Set shipping
March 2005. Recorded Individualy For Type 1 and Type 2 Diabetes, These "LIVE"
5 CD Sets Contain The
Personal Diabetes Education Program taught by Dr. Bernstein to his patients. http://www.diabetes-solution.net/index.php
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
